1 / 3

HIV Prophylaxis_ Lenacapavir Shows Promising Results

A Phase III study aimed at preventing HIV prophylaxis in young African women has shown such promising results that it was terminated early

Healthcare360
Download Presentation

HIV Prophylaxis_ Lenacapavir Shows Promising Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HIV Prophylaxis: Lenacapavir Shows Promising Results (Source-jang.com) A Phase III study aimed at preventing HIV prophylaxis in young African women has shown such promising results that it was terminated early. This development is considered a major advancement in the fight against HIV, particularly in high-risk populations. Study Overview and Results The study compared the e?cacy of lenacapavir, an injectable drug administered twice a year, with two oral pre-exposure prophylaxis (PrEP) medications that prevent HIV prophylaxis replication. Among the 5,338 initially HIV-negative women enrolled, none

  2. of the 2,134 women receiving lenacapavir contracted HIV, whereas 55 women in the oral PrEP groups did. “100 Percent Protection against HIV” Christoph Spinner, an infectiologist at Klinikum rechts der Isar, Technical University of Munich, described the results as groundbreaking. “For the first time, an antiviral drug used preventively shows 100 percent protection against HIV prophylaxis in people with an increased risk of HIV,” he stated. This unprecedented level of e?cacy marks a significant milestone in HIV prophylaxis prevention. Challenges with Current PrEP The lower e?ectiveness of the oral PrEP medications was attributed to inconsistent use among the participants. Many women did not take the medication correctly, leading to insu?cient levels of the active ingredient and reduced protection against HIV prophylaxis. In contrast, the semi-annual injections of lenacapavir were better accepted and adhered to by the participants. The side e?ects of both the injections and the tablets were found to be comparable. Cost and Accessibility Issues Despite the promising results, a significant challenge remains: the high cost of lenacapavir, which limits its accessibility in Africa, a region heavily impacted by HIV prophylaxis. However, e?orts are underway to license the drug to generic manufacturers, which could significantly reduce the price and make it more widely available. The success of lenacapavir in preventing HIV marks a major breakthrough in HIV prophylaxis. With 100 percent protection observed in the study, this injectable drug o?ers a new and potentially more e?ective option for those at high risk of HIV. However, making this life-saving drug a?ordable and accessible remains a critical hurdle to overcome. As discussions about generic licensing progress, there is hope that lenacapavir could soon become a key tool in the global fight against HIV prophylaxis.

  3. Find practical solutions to common challenges through our insightful articles on Healthcare 360 Magazine

More Related